Announcement PDF I m a g i o n B i o s y s t e m s L i m i t e d A S X : I B X S e p t e m b e r 2 0 2 6 Molecular MRI: The Next Generation of Imaging B R E A K T H R O U G H F O R E A R L Y C A N C E R D E T E C T I O N Forward Looking Statements This investor presentation(Presentation) has beenprepared by ImagionBiosystemsLimited (Imagionor the Company).This presentation does not constitute or form part of, and shouldnotbe construedas,anoffer, solicitation or invitation to subscribe for,underwrite or otherwise acquire, any securitiesof Imagionor any member of its group nor shouldit or anypart of itformthe basis of,or be reliedon in connectionwith,any contract topurchase or subscribe for anysecuritiesof Imagionor any member of itsgroup, nor shall it or any part ofit form the basis ofor be reliedoninconnectionwithany contract or commitment whatsoever. This presentation is not aProspectusandcontains summary information about Imagionand its activities, whichiscurrent as atthe date of this presentation. The informationincluded in this presentationis ofa general nature and does not purport to be complete nor does itcontainall the information which aprospective investor shouldconsider whenmaking aninvestmentdecision.Each recipient ofthispresentationshould make its own enquiries andinvestigationsregarding all informationinthispresentation includingbut not limitedtothe assumptions, uncertainties andcontingencies which may affect future operationsof Imagion and the impact thatdifferent future outcomesmayhave on Imagion. Thispresentationhas been prepared without taking accountofany person’s investment objectives, financial situation or particular needs. Before makinganinvestment decision, prospective investors shouldconsider the appropriateness of the information having regard to their own objectives, financial situationandneeds,make their ownassessmentofthe informationandseeklegal, financial, accounting andtaxation advice appropriate totheirjurisdiction in relationtothe information andanyaction takenon the basis of the information. The informationincluded in this presentationhasbeen providedtoyousolely for yourinformation and background and is subject to updating, completion, revision and amendment and such informationmay change materially.Unlessrequired by applicable law or regulation, no person (including Imagion) is under any obligationtoupdate or keepcurrent the informationcontainedinthispresentationand any opinions expressed in relationtheretoare subject tochange without notice. Norepresentationorwarranty,express or implied,is made astothe fairness,currency,accuracy, reasonablenessor completeness of the information containedherein.Neither Imagionnor any other person (including itsshareholders,directors,officers and employees)accepts any liability and Imagion, itsshareholders, itsrelated bodiescorporate and their respective directors, officersandemployees, to the maximum extentpermitted by law, expressly disclaimall liabilitiesfor anylosshowsoever arising, directly or indirectly, from this presentationor itscontents. This presentation includes forward-lookingstatementsthat reflect Imagion's intentions, beliefsorcurrent expectations concerning,amongother things, Imagion's results of operations,financial condition, performance,prospects,growth, strategiesandthe industryinwhich Imagionoperates.These forward- lookingstatementsare subject torisks,uncertainties and assumptions and other factors,manyofwhichare beyondthe control of Imagion. Imagioncautionsyouthat forward-lookingstatementsare notguarantees of future performance and thatits actual results of operations,financial condition, performance, prospects, growthor opportunitiesandthe development ofthe industry in which Imagionoperates may differ materially from those made in or suggestedby the forward-lookingstatementscontainedin this presentation. In addition, Imagiondoes notguarantee anyparticular rate ofreturn or the performance of Imagionnor doesit guarantee the repaymentor maintenance of capital or anyparticular tax treatment. Investorsshould note that pastperformance maynotbe indicative of results or developments infuture periods and cannot be relied uponas an indicator of (and providesnoguidance as to) Imagion's future performance. Imagion, itsrelated bodies corporate andeach of their respective directors, officers and employees and advisersexpressly disclaimany obligationor undertaking to review, update or release any update of or revisionstoany forward- lookingstatementsinthispresentationor any change in Imagion's expectations or any change inevents, conditionsor circumstances on whichthese forward-lookingstatementsare based, except as requiredby applicable lawor regulation. This presentation andanymaterials distributedinconnectionwiththis presentation are not directed to,or intendedfor distribution to or use by, anypersonor entitythat is acitizenor resident or locatedinany locality, state, countryor other jurisdiction where such distribution,publication, availabilityoruse would be contraryto lawor regulationor whichwouldrequire any registrationor licensing withinsuchjurisdiction. The distributionof this presentation in certain jurisdictionsmaybe restricted bylaw andpersons into whose possessionthispresentation comesshould informthemselvesabout and observe anysuch restrictions. 2 IBX Investor Deck | ImagionBiosystems.com • Clinical Stage Biotech in Phase 2 of clinical investigations • Highly Differentiated and first-of-its-kind for cancer detection • Next Generation Tech able to challenge the radiopharmaceutical market Changing How We See Cancer C O M P A N Y O V E R V I E W Strong Pipeline Addressing Large Markets Lead Indication: Prostate Cancer Ovarian Cancer HER2 Breast Cancer (FDA IND Clearance – June 2026) Additional Key Target Indications Include: 3 IBX Investor Deck | ImagionBiosystems.com Screening • Blood-based tests indicate risk but are non-diagnostic and require confirmation before treatment Current Diagnosis Takes Too Long T H E U N M E T M E D I C A L N E E D Biopsy • Provide certainty but are invasive, painful, error prone and challenging, often resulting in side effects or complications • Pathology assessments can take days Conventional Imaging • Non-invasive but non-specific: cannot differentiate benign lesions from malignant tumors with certainty • Gadolinium-based contrast agents are not able to be molecularly targeted MagSense® imaging agents combined with MRI’s high resolution delivers clearer, more confident imaging to support earlier, more definitive diagnoses. M O L E C U L A R M R I MagSense particles are coated with unique targeting moiety specific to a particular type of cancer MagSense particles are administered before an MRI and only bind to targeted type of cancer cells, if present MagSense produce an identifiable change in image contrast, which is easily detected even when tumors are small and at their earliest stages STANDARD MRI MagSense® MRI Radiologist are able to see a CHANGE IN INTENSITY and the spotty pattern resulting when the MagSense imaging agent is present in the tissue Earlier, More Accurate Cancer Detection Lesion or node is irregular in size or shape and considered “suspicious” The change in contrast indicates cancer cells are present MagSense® Imaging Agents Can Be Applied to Many Types of Cancer P L A T F O R M T E C H N O L O G Y – A D D I T I O N A L I N D I C A T I O N S • All MagSense agents work the same, making the regulatory path clear and commercialization and adoption easier • Changing the MagSense targeting molecule allows for detection of different types of cancer • Fits existing clinical workflows and are compatible across 50,000+ MRI scanners in use globally Early Detection of Prostate Cancer • 1M+ Prostate biopsies/year in US • mpMRI = >50% False Positive rate & >15% False Negative rate • PSMA-PET not typically used for primary tumor detection: exposes patients to radioactivity Early Detection of Ovarian Cancer • >300,000 women/yr. diagnosed with ovarian cancer; ~2/3rds die from the disease • 75% of cases diagnosed at late stage • CA-125 blood tests indicate risk but are not predictive of disease • “Watchful waiting” by ultrasound is the existing standard of care Pre-Dose Post-Dose MagSense Ovarian Cancer targeted particle Preclinical xenograph tumor model 6 The Phase 1 Trial in HER2 Positive Breast Cancer Subjects Met All Endpoints1 C L I N I C A L D E V E L O P M E N T • Phase 1 trial conducted in patients with HER2+ breast cancer (N=13) • Imaging agent was generally safe and well tolerated in all patients • Blinded review by independent expert panel of radiologists corroborated detectable magnetic signature Baseline Post-MagSense® Central radiologists called the node “Indeterminate”at baseline and then “Suspicious” post MagSense® imaging, potentially providing true positive finding. Data indicated that MagSense aided in: • Identification of axillary lymph nodes; and • Discrimination of tumor containing lymph nodes from normal lymph nodes • May improve on ultrasound limitations; and • Could reduce need for Sentinel Lymph Node Biopsy and Axillary Lymph Node Dissection 1) ASX release 18 October 2023 7 Baseline Post-MagSense® Central radiologists called the node “Suspicious” at baseline and then “Normal” post MagSense imaging, potentially eliminating false-positive finding. Part A Blood samples taken post dose PK N= 3-10 Objective: Establish further safety profile of MagSense Part B MRIs taken at multiple time points to identify optimal imaging time ImagingSchedule N= 10-20 Objective: Establish lowest dose and post dose imaging schedule Part C MRI @ optimum time based on Parts A & B Diagnostic Performance N=40 Objective: Compare diagnostic performance to Standard of Care Anticipated ~3-6 mos. Anticipated ~6 mos. Anticipated ~12 mos. The Phase 2 HER2+ Clinical Trial C L I N I C A L D E V E L O P M E N T Key Near Term Activities: • Contract 1st clinical site(s) after completing local institutional reviews • Activate site(s) after training on the study protocol and procedures • Open the trial for enrolment and initiate patient recruiting into the trial • First Patient In – dosing of the first patient in Part A • Undertake a Safety Review following the first 3 participants IND Cleared by FDA The Next Generation of Molecular Imaging R A D I O P H A R M A C E U T I C A L S & C O N T R A ST M E D I A M A R K E T L E A D E R S ✓ Gadolinium-Based Contrast Agents improve contrast for high resolution  Risk of higher false positives because it is not specific: both benign and malignant lesions become enhanced  Cannot achieve molecular targeting because of low relaxivity of gadolinium ✓ High sensitivity ✓ Can be molecularly targeted though limited by tracer half-life  Uses Radioactivity  Poor Resolution ✓ No radioactivity: safer for patients and providers ✓ Easier to manufacture & distribute ✓ Works with large installed base of MRI’s ✓ Can be applied to many types of cancer or other diseases ✓ “Theranostic” ready platform able to expand to drug delivery and therapies Contrast Enhanced MRI PET MagSense® mMRI N O N - R A D I O P H A R M A C E U T I C A L T H E R A N O ST I C S • Global cancer incidence to rise 77% by 2050 with screening & diagnostic imaging costs growing at 6.7% CAGR • Molecular imaging to-date limited to methods using radioactivity due to MRI lacking specificity • US$2.1 billion target market for lead indications with upside in theranostics and drug delivery Investment Rationale • High rate of contrast media products achieve regulatory approval (almost 100%) • Imagion Phase 1 clinical data support safety and detectability • Platform technology - all MagSense® imaging agents work the same LARGE MARKETS WITH AN UNMET MEDICAL NEED REDUCED TECHNICAL RISK UPSIDE LEVERAGE • Large ASX Peer Valuations, Potential for Strategic Partnering • ASX radiopharmaceutical companies with multi $B market cap; IBX developing 2.0 proprietary imaging tech • Health economics support value-based reimbursement pricing while still saving healthcare system costs • High gross margins support commercial partnering business model Company Leadership Robert Proulx MAICD Executive Chairman Robert isan operationally oriented executive with over 30 years in life science &medicaldevice product development &commercialisation Experienced team across development & commercialisation of drug & device products Track record of successful marketing approvals Melanie Leydin CA FGIA Co.Sec. and Non-Executive Director Melanie is a Chartered Accountant &a Fellowof the Governance Institute of Australia. She is currently the Managing Director of Vistra Australia Nina Webster PhD, MBA, M.IP.Law Non-Executive Director Nina is an experienced pharmaceutical &biotech executive acrossstrategic planning, scientific & operational execution & commercialisation Brett Mitchell Non-Executive Director Brett isan experiencedASX directorandcorporate finance executive with over 25 years of experience in the venture capital andequity capital markets Ward Detwiler MBA President of US Subsidiary Wardisan experiencedseniorexecutive in the medical imaging field. Most recently, he wasco- founder andCEOof SpinTech MRI Dr. Susan Harvey Medical Affairs Advisor Dr. Harvey is a breast radiologist and the co-founder of CuringWomen’sCancer. Previously she servedas Directorof Breast Imagingat Johns Hopkins Medicine Dr. Kayat-Bittencourt Clinical Advisor Dr. Kayat-Bittencourt is the Vice Chair of Innovation at University Hospitalsand an Associate Professorof Radiology at Case Western Reserve University A B R E A K T H R O U H F O R E A R L Y C A N C E R D E T E C T I O N I m a g i o n B i o s y s t e m s L i m i t e d A S X : I B X i n f o @ i m a g i o n b i o . c o m IBX Investor Deck | ImagionBiosystems.com • FIRST OF ITS KIND IN MOLECULAR MRI • NEXT GENERATION TECH TO DISRUPT RADIOPHARMACEUTICAL MARKET • MULTIPLE INDICATIONS IN DEVELOPMENT • MULTI-BILLION DOLLAR MARKET OPPORTUNITY